Astria Therapeutics 2025 Q3 Earnings Widening Losses Amid Acquisition Plans

Astria Therapeutics (ATXS) reported a net loss of $0.55 per share for Q3 2025, missing the Zacks Consensus Estimate of a $0.41 loss, while revenue remained flat at $706,000 compared to $0 in the prior year. The company reiterated its guidance for the BioCryst acquisition to close in Q1 2026 and highlighted its cash runway extending through 2028.

Revenue

Total revenue for Q3 2025 was $706,000, unchanged from the prior year period. The company missed the Zacks Consensus Estimate by 95.59%, reflecting ongoing challenges in monetizing its pipeline.

Earnings/Net Income

The net loss widened to $31.64 million ($0.55 per share) in Q3 2025, representing a 29% increase from the $24.53 million ($0.42 per share) loss in Q3 2024. The EPS decline of 31% underscores persistent financial pressures.

Price Action

Following the earnings report, ATXS shares gained 0.32% on the day, declined 0.55% for the week, and surged 48.17% month-to-date. The stock’s performance reflects mixed sentiment around the acquisition and clinical trial progress.

CEO Commentary

CEO Jill C. Milne emphasized the BioCryst acquisition as a pivotal opportunity to advance navenibart for HAE, citing benefits for patients and shareholders, including immediate liquidity and continued ownership post-merger.

Guidance

Astria projects sufficient capital to fund operations through 2028, including the completion of key trials for navenibart and STAR-0310. The BioCryst acquisition is pending stockholder approval and expected to close in Q1 2026.

Post-Earnings Price Action Review

The stock’s post-earnings performance has been volatile, with a 48.17% monthly gain contrasting a 0.55% weekly decline. Analysts note that near-term momentum may depend on investor confidence in the acquisition and clinical data.

Additional News

• M&A Activity: BioCryst agreed to acquire Astria in a $8.55 cash and stock deal, pending shareholder approval, to accelerate navenibart’s development.

• C-Level Commentary: CEO Milne highlighted the acquisition’s potential to deliver value to stakeholders and advance HAE treatments.

• Downgrade Alert: Cantor Fitzgerald downgraded ATXS to “Neutral” from “Overweight,” citing execution risks and competitive dynamics in the biopharma sector.

The company’s strategic focus on the BioCryst acquisition and clinical milestones positions it for potential long-term growth, though near-term financial metrics remain a concern for investors.